Department of Medicine, Division of Infectious Diseases, Vanderbilt University Medical Center, Nashville, Tennessee.
Department of Pediatrics, Division of Infectious Diseases, Vanderbilt University Medical Center, Nashville, Tennessee.
J Am Coll Cardiol. 2018 Apr 10;71(14):1574-1583. doi: 10.1016/j.jacc.2018.02.013.
Respiratory syncytial virus (RSV) is historically known for causing respiratory illness in young children, but the appreciation of its impact on older adults is growing. Studies have shown that hospitalization for respiratory illness due to RSV is complicated by cardiovascular events in 14% to 22% of adult patients, including worsening congestive heart failure, acute coronary syndrome, and arrhythmias. Additionally, underlying cardiovascular disease is associated with hospitalization in 45% to 63% of adults with confirmed RSV. In summary, patients with cardiopulmonary disease have higher rates of health care utilization for RSV-related illness and worse outcomes. Patients with cardiovascular disease likely represent an important target population for the rapidly developing field of RSV vaccines.
呼吸道合胞病毒（RSV）在历史上以引起幼儿呼吸道疾病而闻名，但人们对其对老年人影响的认识正在不断增加。研究表明，因 RSV 导致的呼吸道疾病住院患者中有 14%至 22%会并发心血管事件，包括心力衰竭加重、急性冠状动脉综合征和心律失常。此外，45%至 63%确诊 RSV 的成年患者存在潜在心血管疾病，与住院相关。综上所述，心肺疾病患者因 RSV 相关疾病而需要更高的医疗利用率和更差的预后。心血管疾病患者可能代表着 RSV 疫苗这一快速发展领域的一个重要目标人群。
